EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index

EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Company’s products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.